Orsini Selected as Specialty Pharmacy Partner for Crinetics' PALSONIFY™ (paltusotine)

PALSONIFY is an FDA-approved once-daily, oral therapy for the treatment of acromegaly

ELK GROVE VILLAGE, Ill., Sept. 26, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been chosen by Crinetics Pharmaceuticals, Inc., as a specialty pharmacy partner for PALSONIFY™ (paltusotine), a nonpeptide, selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist. PALSONIFY is now the first once-daily, oral treatment approved for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Read the full Prescribing Information at www.PALSONIFY.com. 

Acromegaly develops when a benign pituitary tumor forms and secretes increased levels of growth hormone (GH). Acromegaly is characterized by somatic overgrowth (often in the hands, feet and face), and other physical changes, joint pain, metabolic disorders, cardiovascular disease, and respiratory problems, among others. When left untreated, acromegaly can lead to premature mortality. PALSONIFY is the fifth therapy to join Orsini's Endocrinology Center of Excellence.

"We're honored to stand alongside Crinetics and the acromegaly community to provide access to Palsonify," Brandon Tom, Orsini's CEO, said. "For those living with acromegaly, every step toward effective treatment matters. Orsini is committed to walking that path with patients and healthcare providers, offering compassionate, meaningful support every step of the way."

About Orsini

Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini's high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.

Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, visit www.orsini.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/orsini-selected-as-specialty-pharmacy-partner-for-crinetics-palsonify-paltusotine-302567807.html

SOURCE Orsini